Baseline characteristics of patients with metastatic cancer treated with immune checkpoint inhibitors (ICI) and for which immunophenotyping was performed pre-ICI
| Features | Training cohort | Validation cohort | P value |
| Total | 56 | 33 | |
| Gender | 0.5571 | ||
| Male | 42 (75%) | 23 (69.7%) | |
| Female | 14 (25%) | 10 (30.3%) | |
| Age | 0.4133 | ||
| ≥60 | 16 (28.57%) | 13 (39.39%) | |
| <60 | 40 (71.43%) | 20 (60.61%) | |
| Tumor entity | 0.8186 | ||
| HNSCC | 24 (42.86%) | 16 (48.49%) | |
| NSCLC | 26 (46.42%) | 13 (39.39%) | |
| others | 6 (10.71%) | 4 (12.12%) | |
| Brain metastases | 0.6538 | ||
| Yes | 12 (21.43%) | 5 (15.15%) | |
| No | 44 (78.57%) | 28 (84.85%) | |
| PD-L1 TPS | 0.8995 | ||
| <1% | 19 (33.93%) | 12 (36.37%) | |
| 1%–49% | 18 (32.14%) | 10 (30.3%) | |
| 50%–100% | 17 (30.36%) | 11 (33.33%) | |
| NA | 2 (3.57%) | 0 | |
| Number of previous treatments | 0.7304 | ||
| 0–1 | 22 (39.29%) | 10 (30.3%) | |
| ≥2 | 34 (60.71%) | 23 (69.7%) | |
HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; TPS, tumor proportion score.